Publications by authors named "Jeannot R F Stevens"
Article Synopsis
- Therapeutic drug monitoring (TDM) of TNFα-inhibitors like adalimumab and infliximab is crucial for optimizing dosage and enhancing treatment effectiveness, traditionally done through slow ELISA techniques.
- A new bioluminescent sensor platform called dRAPPID has been adapted for quicker, point-of-care (POC) TDM testing, facilitating easier and faster home-testing options.
- Clinical trials showed that the dRAPPID sensors correlated well with ELISA results, achieving high Pearson's correlation coefficients of up to 0.97, indicating reliability for monitoring patient levels of these drugs.
